PubRank

Maria Pia Brizzi

Author PubWeight™ 11.39‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 2006 1.41
2 Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 2007 1.25
3 Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Clin Cancer Res 2008 1.17
4 Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer. Clin Cancer Res 2002 1.03
5 Gemcitabine and protracted 5-fluorouracil infusion as third-line chemotherapy in refractory colorectal cancer patients. Anticancer Res 2008 0.98
6 Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors. Neuroendocrinology 2011 0.96
7 Presurgical systemic treatment of nonmetastatic breast cancer: facts and open questions. Oncologist 2008 0.86
8 Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study. BMC Cancer 2014 0.86
9 Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy. Breast Cancer Res Treat 2004 0.84
10 Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients. Breast Cancer Res Treat 2010 0.82
11 Intermediate endpoints of primary systemic therapy in breast cancer patients. J Natl Cancer Inst Monogr 2011 0.80
12 Six-year stabilisation of a relapsed pelvic mass from rectal cancer after oxaliplatin-containing chemotherapy. J Cancer Res Clin Oncol 2007 0.79
13 Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist 2015 0.76
14 Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer. Clin Cancer Res 2007 0.75
15 Pharmacoeconomic comparison between chronochemotherapy and FOLFOX regimen in the treatment of patients with metastatic colorectal cancer: a cost-minimization study. Tumori 2004 0.75
16 Is pathologic complete response a valid surrogate parameter of treatment efficacy in HER2 positive breast cancer patients undergoing primary chemotherapy plus trastuzamab? J Clin Oncol 2005 0.75
17 A case of long-term survival after repeated response to oxaliplatin-based chemotherapy and repeated thermoablation of liver metastases from colorectal cancer. Should we introduce the concept of oxaliplatin-resistant tumors? Tumori 2013 0.75
18 Expression analysis of genes involved in DNA repair or synthesis in mixed neuroendocrine/nonneuroendocrine carcinomas. Neuroendocrinology 2015 0.75
19 Acute and fatal thrombocytopenic thrombotic purpura after a single dose of pemetrexed. Int J Clin Pharm 2014 0.75